MedInsights Unleashed
The RASolute 302 trial represents a breakthrough in pancreatic cancer treatment, successfully doubling patient survival compared with standard care. In this episode of MedInsights Unleashed, Prof. Philip Philip, Professor of Medical Oncology, Wayne State University School of Medicine and Henry Ford Cancer Institute, discusses how targeting KRAS mutations may change the treatment landscape for pancreatic cancer, reviews the final ASCO analysis, and explains what these findings mean for patients, caregivers, and clinicians. While not a cure, the study offers new hope by extending survival, improving quality of life, and opening the door to a new era of targeted therapy research.
40 Folgen
Kommentare
0Sei die erste Person, die kommentiert
Melde dich jetzt an und werde Teil der MedInsights Unleashed-Community!